Expected Moves

Release of semi-annual fiscal results for the period ending September 2026. Market focus will be on converting 25.93% top-line growth into positive cash flow after a heavy $11.2M FCF burn.

Expected operational update detailing out-licensing progress and commercial rollout metrics for specialty pharma assets in North American and European markets.

A critical inflection point where the company must address its $54.5M debt load relative to its limited $10.3M cash reserve, potentially forcing a dilutive equity event.